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We consider here how morphogenetic signals involving retinoic acid (RA) are switched on and off in the light of positive and negative
feedback controls which operate in other embryonic signalling systems. Switching on the RA signal involves the synthetic retinaldehyde
dehydrogenase (RALDH) enzymes and it is currently thought that switching off the RA signal involves the CYP26 enzymes which catabolise
RA. We have tested whether these enzymes are regulated by the presence or absence of all-trans-RA using the vitamin A-deficient quail model
system and the application of excess retinoids on beads to various locations within the embryo. The Raldhs are unaffected either by the absence
or presence of excess RA, whereas the Cyps are strongly affected. In the absence of RA some, but not all domains of Cyp26A1, Cyp26B1 and
Cyp26C1 are down-regulated, in particular the spinal cord (Cyp26A1), the heart and developing vasculature (Cyp26B1) and the rhombomeres
(Cyp26C1). In the presence of excess RA, the Cyps show a differential regulation-Cyp26A1 and Cyp26B1 are up-regulated whereas Cyp26C1
is down-regulated. We tested whether the Cyp products have a similar influence on these genes and indeed 4-oxo-RA, 4-OH-RA and 5,6-
epoxy-RA do. Furthermore, these 3 metabolites are biologically active in that they fully rescue the vitamin A-deficient quail embryo. Finally,
by using retinoic acid receptor selective agonists we show that these compounds regulate the Cyps through the RARa receptor. These results
are discussed with regard to positive and negative feedback controls in developing systems.
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The identification of morphogens or signalling molecules
and elaborating how and where they act in the embryo is
one of the most intriguing aspects of developmental biology.
Initially, the mere identification of these signalling mole-
cules—retinoic acid (RA), sonic hedgehog (Shh), fibroblast
growth factor (FGF), Wnts, bone morphogenetic proteins
(BMPs) was a major advance and this was subsequently
followed by the discovery of their pathways of action
between cells and within the cell. As more has been revealed
about the cellular components of a morphogenetic signal, it
has become clear that once such a signal has been turned on,0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2005.06.019
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E-mail address: malcolm.maden@kcl.ac.uk (M. Maden).temporal regulation becomes important and the signal
subsequently needs to be turned off. This has led to the
identification of morphogen antagonists.
There are several ways in which this temporal regulation
could be controlled, the most obvious would be by
transcriptional or translational control of the morphogen,
but this seems not to be the preferred way. Instead, another
factor, an antagonist, is synthesised which interferes with or
destroys the morphogen. For example, the action of the Wnt
proteins are inhibited either by direct binding to secreted
frizzled-related protein or Wnt inhibitory factor, or the Wnt
inhibitors Dickkopf and Wise bind to the Wnt co-receptors
resulting in their removal from the cell surface by internal-
isation making them unavailable for Wnt reception (Logan
and Nusse, 2004). Similarly, in the Shh pathway Hip1 and
Gas1 are proteins localised at the plasma membrane that85 (2005) 224 – 237
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may inhibit Shh by regulating endocytosis or vesicle
transport of Ptc1, the cell surface receptor (Cohen, 2003;
Evans et al., 2003; Eggenschwiler et al., 2001). BMP
signalling is inhibited primarily by molecules such as
chordin, noggin and follistatin binding BMP ligands in the
extracellular space and preventing them interacting with the
cell surface receptors. In addition, there is competition
between the Smads in the cytosol and the ubiquitin ligases
Smurf1 and -2 target Smad1, Smad2 and the cell surface
receptors for degradation by the proteosomes (Munoz-
Sanjuan and Brivanlou, 2002). Fibroblast growth factor
(FGF) signalling through its receptor tyrosine kinase is
inhibited by the sprouty gene family. The FGF signal is
transmitted inside the cell through the Ras/Raf/MAPK
pathway resulting in ERK activation and sprouty acts by
direct binding to these signalling components (Kim and Bar-
Sagi, 2004). These negative feedback systems are wide-
spread in development because they generate stability when
confronted with environmental fluctuations (Freeman,
2000). Conversely, positive feedback loops are normally
considered to generate instability even though there are
examples of this within the pathways discussed above as
well as others (Freeman, 2000). It is therefore of interest to
examine the feedback systems which operate in the RA
signalling system.
RA is a low molecular weight (300 Da), lipophilic,
rapidly diffusing signalling molecule which acts directly on
the nucleus to activate gene expression via heterodimerisa-
tion of the nuclear transcription factors, the retinoic acid
receptors (RARs), and the retinoid X receptors (RXRs)
(Chambon, 1996). The Fon_ signal for RA is its localised
synthesis from retinol via retinal using the retinaldehyde
dehydrogenase enzymes (RALDHs) which oxidise retinal to
all-trans-RA (Duester, 1996, 2000). The Foff_ signal is
considered to be the catabolism of all-trans-RA by the
action of 3 cytochrome P450 enzymes (CYPs), to products
such as 4-oxo-RA, 4-OH-RA and 18-OH-RA (Fujii et al.,
1997; White et al., 1997, 2000). Therefore, one of the keys
to understanding the action of RA is to identify where and
when RA is synthesised and catabolised in the embryo by
examining the distribution of these enzymes and to
determine how these enzymes are regulated by their
substrates.
So far, the distribution of three RALDHs, RALDH1,
RALDH2 and RALDH3 and three CYPs, CYP26A1,
CYP26B1 and CYP26C1 have been described in the
developing embryo. These expression patterns have
revealed a level of subtlety that is not obvious using other
means of identifying RA sites of action. For example, in
mouse and chick embryos, Raldh1 is expressed relatively
late in development and in very restricted regions such as
the dorsal neural retina of the eye and the mesonephros
(McCaffery et al., 1991; Blentic et al., 2003).
All embryos studied express Raldh2 and it appears soon
after gastrulation when it is expressed in the newlygenerated mesenchyme (Berggren et al., 1999; Niederreither
et al., 1997; Swindell et al., 1999). As development
proceeds Raldh2 remains in the mesenchyme of the somites
and lateral plate, and additionally is expressed in the heart
(Moss et al., 1998) and nephrogenic mesenchyme. In mouse
and chick there is little expression of Raldh2 in the head of
the embryo apart from the eye and an area of mesenchyme
caudal to the eye (Blentic et al., 2003). Later, it is expressed
in the meninges around the spinal cord and in the
motorneurons and the roof plate within the spinal cord
(Zhao et al., 1996). In chick, Raldh3 is expressed in very
discrete locations such as the stage 4 Hensen’s node, the
endoderm at the edge of the neural plate below the
developing heart (Blentic et al., 2003). In chick and mouse,
expression of Raldh3 continues in the epithelium abutting
the developing forebrain (Schneider et al., 2001), the ventral
half of the developing eye, the dorsal part of the otic vesicle,
Rathke’s pouch and a stripe at the midbrain/hindbrain
border (Li et al., 2000; Mic et al., 2000).
Cyp26A1 has a fascinating expression pattern which in
some regions is complementary to Raldh2. Expression
begins at the same time as Raldh2, but in a region at the
anterior end of the embryo which is the presumptive
forebrain and midbrain neurectoderm (de Roos et al.,
1999; Fujii et al., 1997; Swindell et al., 1999). In the chick
embryo, it then becomes restricted to the anterior neural
folds, rhombomere 3 in the hindbrain, an equatorial region
of the eye or the dorsal lens and the dorsal third of the
anterior spinal cord. At the posterior end of the embryo,
there is another domain of Cyp26A1 in the tail bud and
hindgut. Cyp26B1 is expressed in the developing vascula-
ture, the heart and the distal mesenchyme of the progress
zone of mouse and chick embryos (MacLean et al., 2001;
Reijntjes et al., 2003). In the chick hindbrain, it has a very
intriguing expression pattern in subsets of neurons within
rhombomeres 2, 4 and 6 and in rhombomere 1 which
contributes to the cerebellum (Reijntjes et al., 2003). In the
chick, Cyp26C1 is expressed in the anterior mesenchyme
and may act as the Fsink_ to Raldh2 which is the Fsource_ of
RA in the posterior mesenchyme in the early embryo, these
two together may help to pattern the overlying neural plate
(Reijntjes et al., 2004). Subsequently, Cyp26C1 is localised
to the head in the neural crest from anterior rhombomeres,
domains of cranial mesenchyme, dynamically in the
rhombomeres and in mouse, the inner ear and tooth buds
(Tahayato et al., 2003).
In the work described here, we have considered whether
the Raldhs and the Cyps are affected by the presence or
absence of RA and the Cyp products. To perform this, we
have, on one hand, used the vitamin A-deficient (VAD)
quail model which develops in the absence of detectable
RA, and on the other hand, we have added RA and other
retinoids on beads to various areas of the chick embryo
where these enzymes are expressed. We find that the Raldhs
are minimally affected by the presence or absence of RA,
whereas the Cyps are dramatically affected both by their
S. Reijntjes et al. / Developmental Biology 285 (2005) 224–237226substrate, RA and their catabolic products leading to a
situation involving positive feedback and resultant degra-
dation of the RA signal. However, we also show that the
Cyp catabolic products are themselves biologically active
which considerably complicates the role of the Cyp
enzymes in RA signalling in the embryo.Materials and methods
Embryos
Vitamin A-deficient (VAD) embryos were obtained from
a colony of quails kept at King’s College London. The
breeding quails are fed on a defined retinoid free diet with
10 mg kg1 of all-trans RA as the only source of vitamin A
in order to permit fertilisation. As RA cannot be detected in
the VAD embryo either by HPLC (Dong and Zile, 1995), by
a F9 reporter cell line (Chen et al., 1995) or by lack of
immunoreactivity with a specific anti-RA monoclonal
antibody (Twal et al., 1995), these embryos are effectively
RA free. The VAD embryos and fertilised hens’ eggs (mixed
flock, Henry Stewart and Co. Ltd., Louth, Lincolnshire)
were incubated in a humidified atmosphere at 37-C.
Embryos were staged according to Hamburger and Hamil-
ton (Hamburger and Hamilton, 1951).
Whole-mount in situ hybridisation
Digoxigenin (Roche) labelled antisense RNA probes for
Cyp26B1 and Cyp26C1 were prepared as described
previously (Reijntjes et al., 2003, 2004). Other probes were
kindly given by E. Swindell (Cyp26A1), R. Godbout
(Raldh1) and F. Grun (Raldh3). Raldh2 was prepared as
described previously (Blentic et al., 2003). Whole-mount in
situ hybridisation was carried out using standard procedures,
prehybridisation and hybridisation was carried out at 70-C
with a probe concentration of 1 Ag/ml and visualised with
digoxigenin antibodies conjugated to alkaline phosphatase
reacted with NBT/BCIP purple (Roche) to give a purple
colour reaction.
Vibratome sectioning of stained embryos
Embryos were embedded in 3.6 ml vibratome embedding
mix (gelatine type A, egg albumin, Sigma, sucrose, BDH),
incubated for 2 h at room temperature and then 400 Al
glutaldehyde (Sigma) was added. Sections were cut at 80
Am on a vibratome (Leica VT 1000S), placed on glass
microscope slides and mounted in glycerol.
Anion exchange resin bead analysis
All-trans-RA (obtained from Sigma), 5,6-epoxy-RA, 4-
oxo-RA and 4-OH-RA (Hoffmann-La Roche, Basel),
CD336, CD2019 and CD437 (a kind gift of Galderma,Sofia Antipolis) compounds were dissolved in 250 Al
dimethyl sulfoxide (Sigma-Aldrich, USA) to a concentra-
tion of 4 mg/ml, placed in a 1.5-ml Eppendorf and analytical
grade anion exchange resin beads AGI-X2, 100–200 Mesh
Formate Form (Bio-RAD) added. Excess retinoid solution
was removed and to visualise the beads 1 ml of Dulbecco’s
MOD Eagle Medium (Gibco) was added. Part of the vitilline
membrane was carefully removed from stage 9 embryos and
1–3 beads placed either by the head or posterior trunk. The
embryos were then incubated for 24 h at 37-C. Before
dissection into PBS and fixation in 4% paraformaldehyde,
the position of the beads relative to the embryo was noted.
Cultures
The hindbrain region of the embryo (including branchial
arches and mesenchyme) and tail bud were dissected from
stage 8 to 10 embryos and cultured in collagen matrix (ICN
Flow), prepared by mixing 1 volume of 7.5% sodium
bicarbonate, 1 volume of 10 medium (DMEM, Gibco) and
eight parts collagen. The pH was adjusted to 7.5 by
dropwise addition of NaOH. The medium consisted of
DMEM-F12 with glutamine (Gibco), 6% glucose, GMS-A
(a trace element mixture of insulin, transferring and
selenium, Gibco) and all-trans-RA (stock solution
1106 M, Sigma). Explants were cultured overnight.
Semiquantitative reverse transcription-PCR analysis
RNAwas isolated from the cultured pieces of embryo by
the guanidinium thiocyanate method of Chomczynski and
Sacchi (1987). For all semiquantitative RT-PCR reactions,
single-stranded cDNA was synthesised from 1 Ag of total
cellular RNA. The cDNA synthesis was achieved by using
M-MuLV reverse transcriptase (Amersham Pharmacia Bio-
tech). One microgram of total RNAwas heated for 10 min at
65-C and then reverse transcribed at 37-C for 1 h using 1 Al
Not I-d(T)18 (5 Ag/Al) diluted 1:25, 1 Al DTT (200 nM) and
5 Al bulk first-strand cDNA reaction mix (murine reverse
transcriptase, RNAguard, Rnase/Dnase free BSA, dATP,
dCTP, dGTP and dTTP) in a 15-Al reaction. The PCR
reaction was carried out using 1 Al of the retrotranscription
reaction in a final volume of 50 Al, containing 10 PCR
buffer, 1.5 mmol/L MgCl2, 200 AM each dNTPs, 0.2 AM
each primer and 1.25 units of Amplitaq DNA polymerase
(Applied Biosystems).
For Cyp26A1 primers were designed using GENbank
accession no. AF199462 to generate a 499-bp product,
for Cyp26B1 primers were designed from ChEST239e5
from the BBSRC Chicken EST Project (Boardman et al.,
2002) http://www.chick.umist.ac.uk to generate a 385 bp
product, for Cyp26C1 from ChEST1007a3 to generate a 514
bp product. The forward and reverse primers were,
respectively, for Cyp26A1 5V-GCCTCTCCAACCTTCA-
CAAC-3V and 5V-GTGGCAGACTCCTTCAGCTC-3V; for
Cyp26B1 5V-TCGGCACTGGCTACCCTCGC-3V and 5V-
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TGCTTTTTTCACCACGG-3V and 5V-TGTGTCACGGAT-
GCTGTACA-3V.
The h-actin gene was co-amplified in each experiment to
verify equal amounts of cDNA in the samples. The
following forward and reverse primers were used 5V-
CGTGACCTGACGGACTACCTV3V and 5V-CTTCT-
GCATCCTGTCAGCAA-3V, designed from GENbank
accession no. L08165 to generate a 398 bp product. The
amplification reaction was initiated by incubation of PCR
samples at 94-C for 3 min followed by the cyclic program,
at 94-C for 30 s, 58-C for 30 s and 72-C for 1 min for 32
cycles for Cyp26A1 amplification, at 94-C for 30 s, 58-C
for 30 s and 72-C for 1 min for 35 cycles for Cyp26B1
amplification and 94-C for 30 s, 58-C for 30 s and 72-C for
1 min for 35 cycles for Cyp26C1 amplification. For each
primer set, an increasing linear number of PCR cycles were
performed with otherwise fixed conditions to determine theoptimal number of cycles to be used. PCR reactions were
performed twice and for each gene the products (20 Al) were
subjected to electrophoresis in 1% (w/v) agarose gel,
visualised by UV after ethidium bromide staining and then
sequenced.Results
Enzyme regulation in the absence of RA
Raldh1
Both normal and VAD quail embryos show the initial
expression of Raldh1 in the dorsal optic vesicle as chick
embryos, beginning at stage 12 (Figs. 1A, B). Thus, the
early expression domain of Raldh1 appears as normal in the
absence of RA. This expression in the eye continues in both
normal and VAD quail embryos at least until stage 18 (Figs.
1E, F) by which time clear structural differences between
the two can be seen. In the normal quail eye (Fig. 1E), the
relatively thick layers of neural retina (nr) and pigmented
retina (pr) can be seen as well as the choroid fissure makingFig. 1. Raldh1 and Raldh2 expression in normal and VAD quail embryos at
various stages of development. (A) Lateral view of the head of a stage 12
normal quail embryo showing Raldh1 expression in the dorsal half of the
eye. (B) Lateral view of the head of a stage 12 VAD quail embryo showing
similar Raldh1 expression in the dorsal half of the eye. (C) Sagittal section
of a stage 16 normal embryo showing Raldh1 expression in the dorsal half
of the eye and the roof of the mesencephalon (arrowhead). (D) Sagittal
section of a stage 16 normal embryo showing Raldh1 expression in the
ventricular layer of the roof of the mesencephalon (arrowhead). (E) Section
of a normal stage 18 eye showing Raldh1 expression in the dorsal half in
both the neural retina (nr) and the pigmented retinal (pr) layers. Arrowhead
marks the choroid tissue. (F) In the stage 18 VAD embryo Raldh1
expression is in the same domains but the retinal layers are very thin and
there is no choroid fissure. pr = Pigmented retina. (G) Ventral view of a
stage 10 normal embryo showing Raldh2 expression in the somites from
the first somite posteriorly and in the inflow tracts of the heart which extend
anteriorly in an arc shape. (H) Ventral view of a stage 10 VAD embryo
showing the same Raldh2 expression in the somites, but a slightly less
extensive anterior expression in the heart tracts (arrowhead). (I) Ventral
view of a stage 14 normal embryo showing Raldh2 expression in the
somites, lateral plate and in the now more developed heart. (J) Ventral view
of a stage 14 VAD embryo showing the same Raldh2 expression as normal
except for a slightly less extensive anterior expression in the heart. (K)
Lateral view of the head of a stage 18 normal embryo showing a v-shaped
expression domain of Raldh2 posterior to the eye (red arrowhead) and
expression in the dorsal pigmented retina. (L) Lateral view of the head of a
stage 18 VAD embryo showing the absence of Raldh2 expression around
and within the eye. (M) Section of a normal stage 20 spinal cord at the
forelimb level showing Raldh2 expression in the developing motor neurons
(red arrowhead). (N) Section of a VAD stage 20 spinal cord at the forelimb
level showing the absence of Raldh2 expression in the region of the
developing motor neurons (red arrowhead). (O) The posterior end of a
normal stage 14 chick embryo showing expression of Raldh2 in the somites
and a small section of unsegmented mesoderm. (P) The posterior end of a
stage 14 chick embryo to which a RA bead had been applied overnight. An
ectopic growth zone expressing Raldh2 has been induced which is growing
laterally (red arrowhead). (Q) A close-up of the somites of an embryo to
which a RA bead had been applied on the left side. The somites are larger
than those on the right side, three of which are marked with red lines.
Fig. 2. Expression of Raldh3 in normal and VAD quail embryos. (A)
Normal stage 4 embryos showing expression in Hensen’s node. (B) VAD
stage 4 embryo showing the same Hensen’s node domain as normal. (C)
Ventral view of a normal stage 10 embryo showing expression in the
ectoderm below the developing forebrain. (D) Ventral view of a stage 10
VAD embryo showing the presence of Raldh3 expression in the anterior
ectoderm, but the domain is much more contracted towards the midline. (E)
Lateral view of a stage 12 normal embryo showing expression in the ventral
eye and ectoderm (red arrowhead). (F) Lateral view of a stage 12 VAD
embryo showing expression in the ventral eye and less extensively in the
ectoderm below (red arrowhead). (G) Lateral view of a stage 18 normal
head showing expression in the isthmus (i), Rathke’s pouch (rp) and in the
ventral eye and adjacent ectoderm. (H) Section of an embryo in G, showing
expression in the isthmus (i) and Rathke’s pouch (rp). (I) Section of a
normal stage 18 eye showing expression in both layers of the ventral half of
the eye and in the ectoderm below the eye. (J) Expression in the head region
of a stage 18 VAD embryo showing expression in the isthmus (i) and the
eye region. (K) A section of the embryo in I shows that there is no Rathke’s
pouch (arrow shows where it ought to be-cf H). (L) Section of a stage 18
VAD eye showing no expression in the ventral part of the eye because there
is no tissue there and expression in the overlying ectoderm instead.
S. Reijntjes et al. / Developmental Biology 285 (2005) 224–237228up the characteristic shape of the forming eye. In the VAD
eye, the neural retina and pigmented retina layers are much
thinner, they are separated by a large gap and there is no
choroid fissure (Fig. 1F).
The later domains of Raldh1 expression described in the
chick, namely a region of endoderm and the mesonephros
do not appear in the quail. Instead, there is a domain in the
mid-sagittal region of the mesencephalon which appears at
stage 16 (Fig. 1C, arrowhead). This domain also appears as
normal in the VAD embryo; indeed, it seems to be
considerably stronger. Sections through such an embryo
show expression in the ventricular layers of the mesence-
phalic neuroepithelium (Fig. 1D). Thus, the absence of RA
has little effect upon Raldh1 expression.
Raldh2
The same expression patterns of Raldh2 that are seen in
the chick are also present in the normal quail embryo and, in
general, there is little change in the VAD embryo. Thus, the
initial appearance of Raldh2 in the mesoderm at stage 4 is
identical in normal and VAD quails (not shown) and this
domain subsequently has an anterior border at the level of
the first somite (Figs. 1G, H). The only difference between
Raldh2 expression in the two embryos is that there is a
subtle absence of expression in part of the heart inflow tracts
(Fig. 1H, arrowhead). This difference remains at later stages
where Raldh2 expression does not extend anteriorly into the
heart inflow tracts in VAD embryos (Fig. 1J) as it does in
the normals (Fig. 1I). Rather than this abnormal heart
expression of Raldh2 being a cause of the subsequent
anatomical heart defects, namely blind ending inflow tracts
(Heine et al., 1985), it is more likely that the abnormal
expression is a reflection of an earlier patterning defect in
the anterior endoderm (Ghatpande et al., 2000).
At later stages of development (stage 18), there are
differences in Raldh2 expression in the head and spinal
cord. In normal quails Raldh2 expression appears in a
patch of mesoderm posterior to the eye and in the
pigmented retina (Fig. 1K) which also appear in chicks.
Both of these domains are absent in the VAD quail embryo
(Fig. 1L). A second late domain of expression which is
missing is expression in the motor neurons in the spinal
cord at limb levels. In chicks and quails, Raldh2 is
expressed in the developing motor neurons (Fig. 1M) and
this is absent in the VAD quail (Fig. 1N). This reflects the
role of RA in motor neuron induction (Sockanathan and
Jessell, 1998) and is mirrored by the down-regulation of
other MN markers in the VAD quail spinal cord (Wilson et
al., 2004). Thus, three late domains of Raldh2 do not
appear in the absence of RA but there is little alteration in
the early domain of Raldh2.
Raldh3
As with the previous two enzymes, the initial expression
of Raldh3 is the same as the chick both in the normal quail
embryo and the VAD embryo. Thus, Hensen’s nodeexpresses Raldh3 in the normal quail embryo (Fig. 2A)
and in the VAD embryo (Fig. 2B). The expression in the
surface ectoderm ventral to the forebrain also appears at the
appropriate time, stage 9/10, but the domain of expression is
much narrower (Figs. 2C, D). This probably reflects a
midline defect present in VAD embryos which results in a
degree of cyclopia and a loss of the ventral part of the eyes.
This narrowness can also be seen at stage 14 when
expression is present in the surface ectoderm ventral to
the eye (Fig. 2E) which is not so laterally extensive in the
VAD embryo (red arrowheads in Figs. 2E, F).
Of the later domains of expression of Raldh3 in the head,
some were normal in VAD quails such as the isthmus (i in
Figs. 2G, H, J, K) and the surface ectoderm overlying the
ventral half of the eye (Figs. 2G, I, J, L), but the other two
domains were missing because of an altered anatomy which
had already become apparent. Thus, the expression of
Raldh3 never appears in the ventral half of the eye in VAD
Fig. 3. Expression of the Cyp genes in normal and VAD quail embryos. (A)
Cyp26A1 in a normal stage 6 embryo showing expression in the anterior
neural plate, lateral edges of the posterior neural plate and the regressing
Hensen’s node. (B) Cyp26A1 in a stage 6 VAD embryo. The anterior neural
plate expression is normal, but the posterior expression is absent. (C)
Cyp26A1 in a normal stage 10 embryo showing expression in rhombomere
3 (red arrowhead), the anterior neural tube and the tail bud. (D) Section
through the embryo in C showing that the neural tube expression of
Cyp26A1 is strongest in the dorsal half. (E) Section through the anterior
spinal cord of a stage 10 VAD embryo showing absence of expression of
Cyp26A1. (F) Cyp26A1 in a stage 10 VAD embryo showing rhombomere 3
expression (red arrowhead) and tail bud expression, but no anterior spinal
cord expression. (G) Lateral view of a stage 16 normal embryo showing
expression of Cyp26B1 in some of the rhombomeres of the hindbrain (hb),
the heart (h) and the developing vasculature, particularly between and
below the somites (bv). Some of the rhombomeres are marked with
numbers. (H) Lateral view of a stage 16 VAD embryo showing expression
of Cyp26B1 remaining in the rhombomeres (numbers) of the hindbrain
(hb), but absent from the heart and vasculature. (I) Lateral view of a stage
14 normal embryo showing expression of Cyp26C1 in some of the
rhombomeres of the hindbrain and the surrounding cephalic mesenchyme.
(J) Lateral view of a stage 14 VAD embryo showing the absence of
expression of Cyp26C1 the rhombomeres of the hindbrain, but it remains in
the surrounding cephalic mesenchyme. (K) Flatmount hindbrain of a stage
22 normal embryo showing discrete expression domains in the individual
rhombomeres (numbered) of the hindbrain. (L) Lateral view of a dissected
hindbrain of a stage 22 VAD embryo showing absence of expression of
Cyp26C1. Rhombomeres are numbered.
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neither does it appear in Rathke’s pouch because that
structure is absent too (rp in Figs. 2G, H vs. arrow in Fig.
2K). Descriptions of these anatomical abnormalities will be
reported elsewhere. Thus again, the changes in the
expression of this enzyme result from loss of anatomical
structures rather than from the absence of its metabolic
product.
Cyp26A1
In the normal quail embryo, as in the chick embryo,
Cyp26A1 expression begins at stage 4 in the anterior
epiblast and expression then expands posteriorly in two
thin lines at the edge of the neural plate where the neural
crest will arise and these lines meet at the tail bud within the
tail bud mesenchyme (Fig. 3A). In VAD-deficient embryos,
the same pattern of expression is seen in the anterior neural
plate, but there is no posterior expression of Cyp26A1 (Fig.
3B). At subsequent stages, the normal anterior expression
spreads throughout the forebrain and midbrain and extends
posteriorly to the rhombomere 3/4 boundary, whereupon the
posterior border regresses anteriorly, leaving a stripe of
expression in rhombomere 3 (Fig. 3C, red arrowhead). In
VAD embryos, which are lacking the posterior rhombo-
meres (r4, 5, 6, 7), the same pattern is seen although the
expression in rhombomere 3 is weaker and does not extend
throughout the dorsoventral extent of the rhombomere (Fig.
3F). Posteriorly at stage 10 in the normal quail, Cyp26A1 is
expressed in the dorsal half of the developing spinal cord
(Figs. 3C, D) and the tail bud (Fig. 3C). In VAD embryos,
the tail bud expression appears (Fig. 3F), although its time
of appearance is delayed, but the spinal cord expression
never appears (Figs. 3E, F). There are, therefore, clear
differences right from the start of Cyp26A1 expression at
neural plate stages between normal and VAD embryos and
these are located in the posterior of the embryo in the
presumptive spinal cord region.
Cyp26B1
We have previously described the expression domains of
Cyp26B1 in the normal and VAD quail embryo (Reijntjes et
al., 2003), but for the sake of completeness they will be
briefly summarised here. In the normal quail embryo,
Cyp26B1 is expressed in the rhombomeres, heart, develop-
ing vasculature, eye, hindgut and limb buds (Fig. 3G). In the
absence of RA Cyp26B1 expression in the trunk is
strikingly absent in the trunk, in the heart and developing
vasculature (Fig. 3H), whereas the rhombomeric expression
is maintained (Fig. 3H, hb). Thus from the outset of
expression Cyp26B1, like Cyp26A1, is repressed in the
trunk in the absence of RA.
Cyp26C1
Cyp26C1 is a Fhead_ gene in the normal quail being
expressed in the very early anterior mesenchyme, anterior
cranial neural crest, specific rhombomeres and discreteregions in the cranial mesenchyme (Reijntjes et al., 2004)
(Figs. 3I, K). The major domain which is absent in the VAD
embryo is the remaining anterior rhombomeres (the
posterior ones are missing) (Figs. 3J, L). Although
expression is still present in the head of VAD embryos
(Fig. 3J), this is in the cranial mesenchyme adjacent to the
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rhombomeres is completely gone (Fig. 3L).
Enzyme regulation in the presence of RA
We next asked whether any of these enzymes could be
up-regulated by the administration of excess all-trans-RA
(tRA) to the embryo. For these experiments, we used local
administration on AG 1-X2 beads soaked in 4 mg/ml all-
trans-RA, a dose which has an in vivo effect of duplicating
the chick limb bud. (Tickle et al., 1982). With local
administration, we could more carefully analyse potential
tissue specific effects and avoid toxicity problems associ-ated with global administration. Beads were applied either
adjacent to the head or to the posterior of stage 8–10
embryos and examined after overnight incubation.
Raldh1, 2 and 3
Control beads which had been soaked in DMSO only
had no effect on the embryos either in terms of Raldh
expression or morphology. The application of tRA soaked
beads had no effect of the expression of Raldh1 or
Raldh3. Regarding Raldh2, there was a minority of
embryos where a tRA bead beside the head caused a
lateral expansion of expression of this enzyme (5 out of
13) because of an anatomical alteration in the structure of
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cardia bifida when applied to chick embryos and this is
what we saw here too (Osmond et al., 1991). When
beads were applied to the posterior end of the embryo
there was, again, a minority of embryos in which Raldh2
expression was expanded, also attributable to an alteration
in anatomy. One change was a conical or blastemal-like
lateral outgrowth from the posterior of the embryo as if the
Fstem cell zone_ had bifurcated (Figs. 1O, P). The second
anatomical effect of tRAwas to cause the generation of larger
somites on the side to which tRAwas applied (Fig. 1Q), the
same effect that has been seen in Xenopus (Moreno and
Kintner, 2004).
Cyp26A1, B1 and C1
Control beads which had been soaked in DMSO only had
no effect on the embryos either in terms of Cyp expression
or morphology. Thus, Cyp26A1 (Fig. 4A), Cyp26B1 (Fig.
4K) and Cyp26C1 (Fig. 4O) were expressed normally in the
presence of these control beads.
tRA soaked beads, however, caused a dramatic change in
the expression patterns of these enzymes. When placed either
at the anterior or posterior end of the embryo Cyp26A1 was
strongly up-regulated by tRA and the up-regulation was
tissue-specific. At the posterior end of the embryo Cyp26A1
was up-regulated in the neural tube and developing vascu-
lature within the splanchnic mesoderm (Figs. 4A vs. B).
Sections through such embryos (Fig. 4C) reveal that there
was more up-regulation in the neural tube on the right side,
the side that the bead was placed (Fig. 4B), than on the left
side of the neural tube suggesting a concentration dependent
effect. These sections also show up-regulation in the
endothelial tubes generating the vasculature, but not in other
tissues such as the lateral plate, somites, notochord or
epithelium (Fig. 4C). When the beads were placed more
anteriorly in the embryo, near the presumptive limb forming
regions then Cyp26A1 was up-regulated in the epitheliumFig. 4. Views of stage 12–14 chick embryos to examine the up-regulation of Cy
position of the beads. (A) The posterior end of an embryo which received a contro
an embryo which received two RA beads showing strong up-regulation of Cyp26A
the embryo shown in B to reveal the differential up-regulation between the left (L
tubes (en) and the lack of up-regulation in the other tissues such as the somites, l
which has up-regulated Cyp26A1 in the ectoderm overlying the presumptive limb
left side (smaller bracket). (E) The anterior end of an embryo showing strong up
regulation in the hindbrain (black arrowhead), up-regulation in the ectoderm over
(bracket on the left), and up-regulation in the anterior spinal cord (sc). (F) An e
demonstrate that Cyp26A1 is not up-regulated in the anterior neuroepithelium. (G)
up-regulation of Cyp26A1 in the cranial mesenchyme. (H) Section through an em
splanchnic mesoderm and endoderm, but not in the neural tube (arrow) or ecto
Cyp26B1 in the endothelial tubes (arrow). (J) Higher power of the section in H sho
the bead (white star) being adjacent to it. (K) The posterior end of an embryo whi
Strong up-regulation of Cyp26B1 in the developing vasculature after the placement
to Cyp26A1—see B. (M and N) Left (M) and right (N) sides of the head of an embr
induction of Cyp26B1 in the cephalic mesenchyme and not the neuroepithelium. (O
virtual lack of expression of Cyp26C1 in the normal embryo. (P) An embryo wh
expression. (Q and R) left (Q) and right (R) sides of the head of an embryo treated
Cyp26C1 in the cranial mesenchyme whereas expression on the right side has beoverlying the future limb (compare left and right sides of Fig.
4D). In the head region, Cyp26A1 was strongly up-regulated
(Fig. 4E) as there is normally no expression of this gene in the
head after neurulation (e.g. Fig. 3C) has been completed.
Further analysis of these embryos by dissection and section-
ing revealed that the up-regulation was only in the pharyngeal
mesoderm (Figs. 4F vs. G) and not in the neuroepithelium of
the developing brain. This differential behaviour between
cranial and trunk neural tissue can be seen in Fig. 4E where
the bead (white asterisk) induced expression in a widespread
area of head mesoderm, the epithelium over the presumptive
limb bud (bracket in Fig. 4E) and in the anterior end of the
spinal cord (sc in Fig. 4E). This spinal cord expression ends at
the spinal cord/hindbrain boundary and there is no up-
regulation in the hindbrain (black arrowhead in Fig. 4E).
Cyp26B1 was also strongly up-regulated by tRA beads
when placed at the posterior end of the embryo in the
developing vasculature (Figs. 4K vs. L). Sections through
this region (Figs. 4H–J) show that in contrast to Cyp26A1,
there was no up-regulation of Cyp26B1 in the neural tube
(black arrow in Figs. 4H and 4L), nor in the ectoderm
(arrow in Fig. 4J) but only in the endothelial tubes within
the splanchnic mesoderm (arrow in Fig. 4I). At the anterior
end of the embryo, Cyp26B1 was up-regulated in the
cephalic mesoderm and not in the developing neuroepithe-
lium (Figs. 4M vs. N).
At the posterior end of the normal control embryo
Cyp26C1 is hardly detectable by in situ hybridisation (Fig.
4O) although it is clearly present when assayed by RT-PCR
(Fig. 5). The presence of tRA had no significant effect (Fig.
4P). This Cyp therefore behaved in a completely different
fashion from the other two. Indeed, when tRA beads were
placed at the anterior end of the embryo a down-regulation
of Cyp26C1 could be detected in the cephalic mesoderm
(Figs. 4Q vs. R).
In order to confirm these differential in situ results we
performed PCR experiments using stages 8–10 tail bud orp26A1, B1 or C1 by all-trans-RA applied on a bead. White stars mark the
l bead showing the normal expression of Cyp26A1. (B) The posterior end of
1 in the neural tube and in the developing vasculature. (C) A section through
) and right (R) sides of the neural tube, the up-regulation in the endothelial
ateral plate or notochord. (D) An embryo with a bead placed near the head
bud on the right side (bracket) compared with its normal expression on the
-regulation of Cyp26A1 in the head mesenchyme (around the star), no up-
lying the presumptive limb bud (bracket on the right) compared to the left
mbryo such as the one in E which has had the mesenchyme removed to
An embryo with a less dramatic effect than the one in E showing localised
bryo showing the up-regulation of Cyp26B1 in the developing vasculature,
derm. (I) Higher power of the section in H showing the up-regulation of
wing the lack of up-regulation of Cyp26B1 in the ectoderm (arrow) despite
ch received a control bead showing the normal expression of Cyp26B1. (L)
of two RA beads, but no up-regulation in the neural tube (arrow) in contrast
yo which was treated with two RA beads on the right side showing localised
) The posterior end of an embryo which received a control bead showing the
ich received a RA bead showing a lack of an inductive effect on Cyp26C1
with a RA bead on the right side. The left side shows normal expression of
en down-regulated around the bead (white star).
Fig. 6. The effect of 3 Cyp26 metabolites, applied on a bead, on Cyp26
expression. White stars mark the position of the bead. (A) 4-oxo-RA
strongly induces Cyp26A1 expression in the developing vasculature (black
arrowheads) and in the neural tube (white arrowhead). (B) 4-oxo-RA
strongly induces Cyp26B1 in the developing vasculature. (C) 4-oxo-RA
down-regulates Cyp26C1 in the cranial mesenchyme on the right side
where the bead was placed (red arrowhead) and on the left side the
expression is normal (black arrowhead). (D) 5,6-epoxy-RA up-regulates
Cyp26A1 expression in the neural tube (white arrowhead), the ectoderm
over the presumptive limb bud (black arrowhead) and the developing
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overnight. Fig. 5, upper panel, confirms that Cyp26A1 in
anterior embryonic tissue was up-regulated by 106 M tRA
(lane 2) compared to untreated control anterior embryonic
tissue (lane 1) and that tail bud tissue behaved in the same
way (control tail bud tissue lane 3 compared to 106 M tRA
treated tail bud tissue lane 4). Fig. 5 (second panel) shows
that Cyp26B1 was up-regulated in anterior tissue by 106 M
tRA (lane 2 compared to lane 1 untreated tissue) as was
Cyp26B1 in tail bud tissue (untreated tissue lane 3 compared
to 106 M tRA treated lane 4). In contrast, Cyp26C1 (Fig. 5,
third panel) was clearly down-regulated by 106 M tRA
both in anterior tissue (lane 2 compared to untreated control
tissue, lane 1) and tail bud tissue (untreated lane 3 compared
to 106 M tRA treated lane 4).
Do the Cyp enzyme products affect the expression of the
Cyps?
Since all-trans-RA does not affect the expression of the
enzymes which synthesise it (the Raldhs), we next consid-
ered whether the same behaviour was exhibited by the Cyp
products. The Cyps metabolise tRA into various polar
compounds including 5,6-epoxy-RA, 4-oxo-RA, 4-OH-RA
and 18-OH-RA (White et al., 1996, 2000; Fujii et al., 1997).
We used three of these compounds 5,6-epoxy-RA, 4-oxo-RA
and 4-OH-RA to determine whether they would affect Cyp
expression in the way that tRA does. As with the tRA
experiments, these compounds were administered at a
concentration of 4 mg/ml on beads.
4-oxo-RA administration produced the same effects as
tRA. It strongly up-regulated Cyp26A1 in the neural tube,
tail bud and developing vasculature (Fig. 6A). It strongly
up-regulated Cyp26B1 in the developing vasculature (Fig.
6B) and down-regulated Cyp26C1 in the cephalic meso-
derm (Fig. 6C, red arrowhead). 5,6-epoxy-RA behaved theFig. 5. Semiquantitative RT-PCR experiments on chick tissue from the
anterior of the embryo (hindbrain plus associated cranial mesenchyme) and
the tail bud cultured in 106M tRA overnight. Lane 1, control anterior tissue;
lane 2, anterior tissue + 106M tRA; lane 3, control tail bud tissue; lane 4, tail
bud + 106M tRA. The upper panel shows the results for Cyp26A1
expression with an increase in expression after the addition of tRA; the upper
middle panel shows the results for Cyp26B1 expression with an increase in
expression after the addition of tRA; the lower middle panel shows the results
for Cyp26C1 expression with a sharp decrease in expression after the
addition of tRA; the lower panel shown no change in the expression of actin
with tRA.
vasculature (red arrowhead). (E) 5,6-epoxy-RA up-regulates Cyp26B1
expression in the developing vasculature. (F) 5,6-epoxy-RA down-regulates
Cyp26C1 in the cranial mesenchyme on the right side (red arrowhead)
where the bead was placed and on the left side its expression is normal
(black arrowhead). (G) 4-OH-RA up-regulates Cyp26A1 expression in the
neural tube (white arrowhead) and the developing vasculature (black
arrowhead). (H) 4-OH-RA up-regulates Cyp26B1 expression in the
developing vasculature. (I) 4-OH-RA down-regulates Cyp26C1 expression
in the cranial mesenchyme on the right side where it was placed and on the
left side its expression is normal.same in up-regulating Cyp26A1 in the neural tube,
epithelium overlying the presumptive limb bud and deve-
loping vasculature (Fig. 6D), up-regulating Cyp26B1 in the
developing vasculature (Fig. 6E) and down-regulating
Cyp26C1 in the cephalic mesoderm (Fig. 6F, right side).
4-OH-RA also behaved the same in up-regulating Cyp26A1
in the neural tube and developing vasculature (Fig. 6G), up-
regulating Cyp26B1 in the developing vasculature (Fig. 6H)
and down-regulating Cyp26C1 in the cephalic mesoderm
(Fig. 6I, right side). The only differences between these
Fig. 7. (A–F) The effect of receptor selective agonists on Cyp26A1 (A–C)
and Cyp26B1 (D–F) expression. (A) Up-regulation of Cyp26A1 in the
neural tube (white arrowhead) and developing vasculature (red arrowheads)
by CD336, a RARa selective compound. Compare with C which shows a
normal level of Cyp26A1 expression. (B) Less extensive up-regulation of
Cyp26A1 in the neural tube (black arrowhead) by CD2019, a RARh
selective compound. (C) Lack of effect of CD437, a RARg compound, on
Cyp26A1 expression. Only the normal expression in the tail bud is
apparent. (D) Massive up-regulation of Cyp26B1 in the developing
vasculature by CD336, a RARa selective compound. (E) Less extensive
up-regulation of Cyp26B1 in the developing vasculature (red arrowhead) by
CD2019, a RARh selective compound. (F) Lack of effect of CD437, a
RARg compound, on Cyp26B1 expression. Only the normal expression in
the vasculature in the lateral plate and between the somites is apparent.
(G–K) Rescue of the VAD embryo by Cyp products. (G) Normal stage 19
quail embryo. (H) VAD stage 19 quail embryo at the same magnification as
G showing how small these embryos are and with their extensive
developmental defects—small head, missing posterior hindbrain, small
somites, symmetrical heart, absent vitelline veins. (I) VAD embryo treated
with beads of 4-oxo-RA showing a complete phenotypic rescue. (J) VAD
embryo treated with beads of 5,6-epoxy-RA showing a complete phenotypic
rescue. (K) VAD embryo treated with beads of 4-OH-RA showing a
complete phenotypic rescue.
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effect on the levels of up- or down-regulation than the other
two compounds.
Which of the RARs does RA act through to alter Cyp
expression?
There are three RARs present in higher vertebrate
embryos and each of them may act on different target
genes. We next used RAR selective agonists to determine
which RAR is responsible for altering Cyp expression.
These compounds have a far higher affinity for either
RARa, RARh or RARg: CD336 is RARa selective,
CD2019 is RARh selective and CD437 is RARg selective.
They were administered overnight at a concentration of 4
mg/ml on beads as in the previous experiments. The next
day, the embryos were examined for Cyp26A1, Cyp26B1 or
Cyp26C1.
Cyp26A1—the RARa selective compound strongly up-
regulated Cyp26A1 in the neural tube and only weakly in
the developing vasculature in 7 out of 9 embryos (Fig. 7A)
and weakly induced it in the remaining 2 embryos. The
RARh selective compound produced a very weak up-
regulation in the neural tube in 4 out of 9 embryos and had
no effect on the remaining 5 embryos (Fig. 7B). The RARg
selective compound generated a very weak alteration of
expression in 4 out of 10 embryos and had no effect on the
remaining 6 embryos (Fig. 7C). From this, we conclude that
Cyp26A1 is primarily regulated by RARa.
Cyp26B1—the RARa selective compound generated a
massive up-regulation of Cyp26B1 in the developing
vasculature in 100% of embryos (Fig. 7D). The RARh
selective compound produced a weak up-regulation in the
developing vasculature in 4 out of 9 embryos and had no
effect on the remaining 5 embryos (Fig. 7E). The RARg
selective compound had a minor effect on only 1 out of 9
embryos and the remaining 8 embryos showed normal
expression. From this, we conclude that Cyp26B1 is regu-
lated by RARa.
Cyp26C1—the RARa selective compound had an effect
in down-regulating Cyp26C1 expression in the cranial
mesenchyme in only 5 out of 11 embryos with the
remaining 6 embryos showing normal expression (data not
shown). Neither the RARh selective compound nor the
RARg selective compound had any effect on Cyp26C1
expression. From this, we conclude that Cyp26C1 is
regulated by RARa.
Are the Cyp products biologically active?
The up-regulation of Cyp26A1 and B1 and the down-
regulation of C1 by the Cyp products implies that they are
potentially biologically active molecules. To test this, we
next asked whether they could rescue the VAD quail
phenotype. When administered prior to the early somite
stage retinol and tRA can completely rescue, all the varioussystem defects in the VAD quail embryos so that they
develop normally and survive (Gale et al., 1999). By
administering these compounds at a concentration of 4 mg/
ml on beads at stages 6–7, we could also rescue VAD quail
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respectively. The VAD quail is far smaller has a defective
neuroepithelium including a missing posterior hindbrain,
smaller somites, missing vitelline veins and a symmetrical
heart with a blind ending inflow tract. Fig. 7I shows that 4-
oxo-RA can rescue the VAD quail so that it is indistinguish-
able from a normal one, as can 5,6-epoxy-RA (Fig. 7J) and
4-OH-RA (Fig. 7K).Discussion
In the work described here, we have studied the
regulation of the enzymes which metabolise and catabolise
all-trans-RA, namely the RALDHs and the CYP26s during
avian development. We have performed this firstly, by
examining the expression of these enzymes in the absence
of RA using the VAD quail model and secondly, by
examining their expression in the presence of ectopic tRA.
Since RA signals are crucial in the morphogenesis of
various embryological systems – the hindbrain, the heart,
the eye, the urogenital system, neuronal development in the
spinal cord – it is important to understand how such a signal
is switched on and off in one location and then on and off in
another location.
The RALDHs synthesise RA from retinaldehyde and
generate a RA signal that is capable of affecting both the
cells that synthesise it and cells in adjacent tissues into
which it could diffuse. Since negative feedback is an
important aspect of homeostatic control systems we have
asked whether tRA affects Raldh gene expression in such a
fashion. The mechanism of switching off the RA signal is
currently thought to involve the Cyp enzymes which
catabolise tRA into downstream, and supposedly inactive,
metabolites. Since positive feedback is another important
aspect of developmental control mechanisms, we have
asked whether tRA or the downstream metabolites affect
Cyp gene expression.
With regard to the RALDHs we showed that the
expression of neither Raldh1, Raldh2 nor Raldh3 was
altered in the absence of RA, that is, their domains of gene
expression appeared largely as normal in the VAD quail
embryo. Similarly, when a bead which had been soaked in
tRA was placed at the anterior or posterior of the chick
embryo then ectopic expression of these Raldhs was not
detected. There were some minor expansions of expression
domains caused by the induction of anatomical changes. For
example, there was an enlarged domain of Raldh2 around
the heart, caused by the appearance of cardia bifida, which
is a known effect of RA application (Osmond et al., 1991).
RA application also induced larger somites as has been seen
in Xenopus (Moreno and Kintner, 2004) and a curious
ectopic blastema-like structure at the posterior end of the
embryo which seemed to be branching off from the Fstem
cell zone_. It is very interesting that excess RA (these
results; Moreno and Kintner, 2004) and a lack of RA(Maden et al., 2000) or an inhibition of RA signalling
(Moreno and Kintner, 2004) generate larger and smaller
somites respectively and in this regard, RA seems to act
through a gene called Thy1 to interact in a negative fashion
with FGF signalling in the presomitic mesoderm (Moreno
and Kintner, 2004).
This limited effect of RA on Raldh expression in
embryos is supported by other in vivo and in vitro data.
For example, tRA had no effect on Raldh2 expression in the
mouse embryo except at one particular stage when it acted
indirectly to down-regulate it (Niederreither et al., 1997).
Neither tRA nor 9-cis-RA affected Raldh2 expression in
human embryonic kidney cells and the explanation is that
no retinoic acid response elements (RARE) or retinoid X
response elements could be detected in the promoter
upstream from the transcription start site (Wang et al.,
2001). However, RA down-regulates Raldh2 in the zebra-
fish (Dobbs-McAuliffe et al., 2004) so there may be some
species-specific differences in the response of this gene to
RA.
In contrast to the Raldhs, the Cyps were strongly affected
both by the absence and presence of excess RA. In the
absence of RA, specific domains of the Cyps were missing.
For Cyp26A1, the domain which localises to the presump-
tive spinal cord was missing whereas the anterior neural
domain in the presumptive forebrain, midbrain and anterior
hindbrain and the tail bud domain were normal. This same
result is seen in the Raldh2/ mouse (Molotkova et al.,
2005). This may contribute to an explanation of the
abnormal dorsoventral organisation which is seen in the
anterior spinal cord in the absence of RA (Wilson et al.,
2004). For Cyp26B1, the posterior domain which localises
to the developing vasculature and heart is missing, whereas
the anterior domain in the rhombomeres appears as normal.
This suggests a role for Cyp26B1 in the development of the
cardiovascular system. In zebrafish, however, the develop-
ment of the common cardinal vein, at least, is abnormal after
Cyp26A1 inhibition (Emoto et al., 2005). For Cyp26C1, the
rhombomeric domains in the hindbrain were missing
whereas the expression in the cranial mesenchyme was
normal which suggests a role for Cyp26C1 in rhombomere
patterning. The absence of Cyp26A1 and B1 expression in
the trunk of the embryo and their induction by RA accords
well with the endogenous supply of RA in the embryo
which arises in the main from Raldh2 in the paraxial
mesoderm.
Excess tRA induced the strong up-regulation of
Cyp26A1 in the developing vasculature, neural tube,
ectoderm over the presumptive limb bud and cranial
mesenchyme. The neural tube and limb bud ectoderm are
normal sites of expression of Cyp26A1, whereas the
vasculature is a site of Cyp26B1 and the cranial mesen-
chyme is a site of Cyp26C1 expression. Therefore, each
gene seems to be able to be expressed in any of the FCyp
domains_, but not in regions where the Cyps are never
expressed, for example, in the somites or in the early
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induced in the cranial mesenchyme and developing vascu-
lature, but not elsewhere.
Cyp26C1, however, displayed the opposite effect to the
other two Cyps and its expression in the cranial mesen-
chyme was down-regulated by excess tRA. This surprising
differential result was confirmed using RT-PCR-Cyp26A1
and B1 are induced by tRA and Cyp26C1 is repressed. By
using synthetic retinoids which show preferences for differ-
ent retinoic acid receptors (RARs), that is, RAR agonists, we
showed that the up-regulation of Cyp26A1 and B1 and the
down-regulation of Cyp26C1 operates primarily through
RARa. This is not the same result that has been seen in
transactivation assays using the three receptors. Of the Cyp
products, 4-oxo-RA most effectively activated RARa and
RARh, 4-OH-RAwas only efficient at activating RARh and
5,6-epoxy-RA most effectively activated RARg (Idres et al.,
2002). Presumably the in vivo situation differs from trans-
activation assays or the chick RARs behave differently from
those of the mouse. The positive and negative feedbacks that
we have observed are summarised in Fig. 8.
It is well established that the Cyps are RA-inducible, but
their differential behaviour that we have observed here in
that Cyp26C1 was down-regulated by RA is novel.
Cyp26A1 is up-regulated by RA in EC cells (Abu-Abed et
al., 1998; Fujii et al., 1997; Ray et al., 1997), various human
cell lines (White et al., 1997) in zebrafish (White et al.,
1996) and in adult mouse liver, but not in brain (Ray et al.,
1997). This is because the upstream region of the promoter
contains a RARE which is conserved between zebrafish,
mouse and human to which RARg and RXRa proteins bind
(Loudig et al., 2000). In mutant mouse F9 cell lines, there is
a decrease in the levels of induction of Cyp26A1 in a
RARg/ mutant line and no induction in a RARg//
RXRa/ double mutant line suggesting that these are the
nuclear receptors responsible (Abu-Abed et al., 1998). This
contrasts with our result of the induction of Cyp26A1 in the
chick embryo with a RARa agonist and the complete
inactivity of a RARg agonist, suggesting a species-specific
response. The response of Cyp26A1 to excess tRA in the
mouse embryo is also different to our results in the chick.
The anterior of the mouse embryo up-regulates Cyp26A1
whilst at the posterior end of the embryo it is down-
regulated (Fujii et al., 1997) and in the Xenopus embryo the
same differential phenomenon in different regions of the
embryo is seen (Hollemann et al., 1998). Nevertheless, theFig. 8. Summary of the RA synthesis and catabolism pathway (black
arrows) and the regulatory interactions we have described (red arrows).response of Cyp26A1 in the embryos of both mouse and
chick to a lack of RA is identical (Molotkova et al., 2005) so
it may be that the elimination of RA is a better test of
whether a gene is normally regulated by RA than observing
the effects of excess RA.
Cyp26B1 seems to be consistently up-regulated by
excess RA in three human cell lines, but not in another
(White et al., 2000) as it is in the chick embryo. We suggest
that this induction occurs primarily through the RARa
receptor. With regard to Cyp26C1, the only report of its
inducibility is in human keratinocyte cell lines where it is
up-regulated (Taimi et al., 2004), whereas we show here that
it is down-regulated in the chick embryo.
This induction of Cyp26A1 and B1 by their substrate,
tRA, which catabolises it into downstream products makes
perfect sense in terms of the control of morphogenetic
signalling. As considered in Introduction, after a signal has
been generated (tRA), there should be a pathway induced to
switch it off and so the induction of an enzyme which will
destroy tRA and act as a negative regulator seems very
logical. The tissues in which this phenomenon occurs are
the spinal cord (Cyp26A1) and the trunk vasculature and
heart (Cyp26B1) that is, regions adjacent to Raldh2
expression. On the other hand, there are certain regions
where the Cyp26s are not induced by RA as highlighted by
their normal expression in the VAD quail: the anterior neural
and tail bud expression of Cyp26A1 and the rhombomeric
expression of Cyp26B1. These considerations do not apply,
however, to Cyp26C1 which is down-regulated by tRA and
in this case it is acting as a positive regulator.
The action of Cyp26A1 and B1 as negative regulators is
further reinforced by our findings that at least three of the
products of Cyp metabolism, 4-oxo-RA, 4-OH-RA and 5,6-
epoxy-RA themselves feedback and up-regulate Cyp
expression and this up-regulation takes place within exactly
the same tissues as found for tRA. This similarity in effect
also applies to Cyp26C1 which is down-regulated in the
same tissue by these Cyp products. However, the simplicity
of this signalling pathway may be somewhat tempered by
our observations that these Cyp products, 4-oxo-RA, 4-OH-
RA and 5,6-epoxy-RA are themselves biologically active
and can act as morphogenetic signals. In our assay of
biological activity, we used the VAD quail and showed that
these three compounds can fully rescue these embryos which
would otherwise have multiple organ defects.
The biological activity of Cyp products has been seen in
several other situations. 4-oxo-RA alters anteroposterior
pattern in the Xenopus embryo through its activation of
RARh (Pijnappel et al., 1993; Nikawa et al., 1995) and it
can rescue the cardiovascular defects in the VAD quail
(Kostetskii et al., 1998). Over-expression of Cyp26A1 in EC
cells should inactivate RA as has been seen many times and
thus reduce its differentiating potential, but when these
cells are left to differentiate, they turn into neurons
(Sonneveld et al., 1999). In mouse skin 4-oxo-RA, 4-OH-
RA and 5,6-epoxy-RAwere active in changing the epidermal
S. Reijntjes et al. / Developmental Biology 285 (2005) 224–237236thickness (Reynolds et al., 1993) and 4-oxo-RA can restore
sperm production in vitamin A-deficient mice (Gaemers et
al., 1996). In various cell culture lines, these same catabolites
inhibited the proliferation and induce differentiation of breast
cancer cells (van der Leede et al., 1997; Van Heusden et al.,
1998), rhabdomyosarcoma tumour cells (Ramp et al., 1994)
and NB4 promyelocytic leukaemia cells (Idres et al., 2001).
Interestingly with regard to our results in the chick embryo,
the latter effect operates through the RARa receptor. The
result of this positive feedback of the two Cyps, A1 and B1
by their products would lead to the generation of even greater
levels of the biologically active catabolic products and
presumably a situation of instability. However, it is notable
that these results were obtained either using cultured cell
lines or with a concentration of retinoids in excess of normal
physiological levels. In the mouse embryo, the tail bud
defects resulting from the absence of Cyp26A1 can be
rescued by reducing the levels of tRA signalling (Nieder-
reither et al., 2002) and in Xenopus, ectopic expression of
Cyp26A1 rescues the embryo from the deleterious effects of
excess RA (Hollemann et al., 1998). These results suggest
that at least Cyp26A1 does control the physiological level of
tRA. Perhaps therefore in vivo the potentially biologically
active Cyp26 products are rapidly further oxidised and do
not accumulate to levels which would interfere with tRA
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